FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Dr. Reddys Hit With Form-483 After API Inspection

[ Price : $8.95]

A recent inspection at Dr. Reddys Laboratories active pharmaceutical ingredient manufacturing plant in Middleburg, NY cites three ...

High-Risk Groups Should Avoid Amalgam Fillings: FDA

[ Price : $8.95]

FDA says it now recommends that people in seven high-risk categories refrain from exposure to dental mercury amalgam when possible...

Sandoz $195 Million Fine in Price Fixing Scheme

[ Price : $8.95]

Sandoz agrees to pay a $195 million criminal penalty under a deferred prosecution agreement in an ongoing generic drug price-fixin...

Panel Recommends Against Mercury-containing Amalgam

[ Price : $8.95]

FDAs Immunology Devices Panel of the Medical Devices Advisory Committee recommends that FDA should require dentists to move away f...

FDA Update on Ranitidine Contaminant Testing

[ Price : $8.95]

FDA says it is continuing to test ranitidine products from multiple manufacturers and is assessing the potential impact on patient...

FDA Requires New Gadolinium Agent Warning

[ Price : $8.95]

FDA says it will require a new Warning and other steps to inform patients and healthcare professionals about the risk of gadoliniu...

Dr. Reddys Duvvada Facility Cited by FDA Again

[ Price : $8.95]

FDA issues a 13-item FDA-483 to Dr. Reddys oncology drug manufacturing facility at Duvvada, Visakhapatnam, India.

FDA Releases Dr. Reddys Warning Letter

[ Price : $8.95]

FDA releases its 11/5 Warning Letter to Dr. Reddys Laboratories detailing findings from inspections at three of the companys facil...